以药剂师为主导的指导心力衰竭的药物治疗:对初级保健的影响分析

IF 1.6 Q4 HEALTH CARE SCIENCES & SERVICES
Markus Schichtel, Stephen Barclay, Helena Papworth, Leila Mills, Ben Bowers
{"title":"以药剂师为主导的指导心力衰竭的药物治疗:对初级保健的影响分析","authors":"Markus Schichtel, Stephen Barclay, Helena Papworth, Leila Mills, Ben Bowers","doi":"10.1136/bmjoq-2025-003401","DOIUrl":null,"url":null,"abstract":"<p><p>Optimal guideline-directed medical therapy (GDMT) can reduce mortality, unplanned hospital admissions and improve quality of life for patients suffering from heart failure (HF). However, GDMT remains underused in primary care. Only a minority of patients on HF registers receive optimal GDMT in the UK. This suboptimal care is compounded by a mounting lack of GP capacity and the growing burden of HF.A multisite, quantitative impact analysis was undertaken to evaluate the optimisation of HF patients by a novel pharmacist-led GDMT model in UK primary care.We identified low-risk HF patients suitable for pharmacists' input, including a community validated risk stratification tool-the HF Event STrengthening Score. The primary outcome was to compare the proportion of patients on optimal HF GDMT at 6 months and 2 years with baseline. Secondary outcomes were direct personnel healthcare costs and GP workload. A subgroup analysis was modelled to estimate effect on mortality, hospitalisation and quality of life.A total of 237 patients were included. Pharmacist-led GDMT contributed to the increase of optimal GDMT from 17.7% at baseline to 76.5% at 6 months and 94.5% at 2 years follow-up. The novel approach reduced GPs' HF GDMT workload by 36.6% at 6 months and 42.1% at 2 years and healthcare costs by 18.4% at 6 months and 20.3% at 2 years. Patients with combined angiotensin receptor neprilysin inhibitor/sodium glucose co-transporter 2 inhibitor treatment indicated a reduction of 20.8% in cardiovascular mortality, a reduction of 34.8% in hospitalisations and a 5.31 Kansas City Cardiomyopathy Questionnaire Score for improved quality of life at 2 years.For low-risk HF patients, pharmacist-led optimisation achieved significantly higher GDMT rates, reduced personnel healthcare costs, reduced GPs' workload, contributed to reduced cardiovascular mortality, reduced hospitalisations and improved quality of life. In the context of current workload pressures, this approach should be considered for widespread implementation in general practice.</p>","PeriodicalId":9052,"journal":{"name":"BMJ Open Quality","volume":"14 3","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406906/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.\",\"authors\":\"Markus Schichtel, Stephen Barclay, Helena Papworth, Leila Mills, Ben Bowers\",\"doi\":\"10.1136/bmjoq-2025-003401\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Optimal guideline-directed medical therapy (GDMT) can reduce mortality, unplanned hospital admissions and improve quality of life for patients suffering from heart failure (HF). However, GDMT remains underused in primary care. Only a minority of patients on HF registers receive optimal GDMT in the UK. This suboptimal care is compounded by a mounting lack of GP capacity and the growing burden of HF.A multisite, quantitative impact analysis was undertaken to evaluate the optimisation of HF patients by a novel pharmacist-led GDMT model in UK primary care.We identified low-risk HF patients suitable for pharmacists' input, including a community validated risk stratification tool-the HF Event STrengthening Score. The primary outcome was to compare the proportion of patients on optimal HF GDMT at 6 months and 2 years with baseline. Secondary outcomes were direct personnel healthcare costs and GP workload. A subgroup analysis was modelled to estimate effect on mortality, hospitalisation and quality of life.A total of 237 patients were included. Pharmacist-led GDMT contributed to the increase of optimal GDMT from 17.7% at baseline to 76.5% at 6 months and 94.5% at 2 years follow-up. The novel approach reduced GPs' HF GDMT workload by 36.6% at 6 months and 42.1% at 2 years and healthcare costs by 18.4% at 6 months and 20.3% at 2 years. Patients with combined angiotensin receptor neprilysin inhibitor/sodium glucose co-transporter 2 inhibitor treatment indicated a reduction of 20.8% in cardiovascular mortality, a reduction of 34.8% in hospitalisations and a 5.31 Kansas City Cardiomyopathy Questionnaire Score for improved quality of life at 2 years.For low-risk HF patients, pharmacist-led optimisation achieved significantly higher GDMT rates, reduced personnel healthcare costs, reduced GPs' workload, contributed to reduced cardiovascular mortality, reduced hospitalisations and improved quality of life. In the context of current workload pressures, this approach should be considered for widespread implementation in general practice.</p>\",\"PeriodicalId\":9052,\"journal\":{\"name\":\"BMJ Open Quality\",\"volume\":\"14 3\",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406906/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Quality\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjoq-2025-003401\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Quality","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjoq-2025-003401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

最佳指导药物治疗(GDMT)可以降低心力衰竭(HF)患者的死亡率、计划外住院率和改善生活质量。然而,GDMT在初级保健中仍未得到充分利用。在英国,只有少数心衰患者接受了最佳的GDMT治疗。这种次优护理因全科医生能力的日益缺乏和心衰负担的日益加重而复杂化。一项多地点、定量影响分析被用于评估在英国初级保健中由药剂师主导的新型GDMT模型对心衰患者的优化。我们确定了适合药剂师介入的低风险HF患者,包括社区验证的风险分层工具- HF事件强化评分。主要结果是比较在6个月和2年时接受最佳HF GDMT治疗的患者比例。次要结局是直接人员医疗保健费用和全科医生工作量。建立亚组分析模型来估计对死亡率、住院率和生活质量的影响。共纳入237例患者。药剂师主导的GDMT使最佳GDMT从基线时的17.7%增加到6个月时的76.5%和2年随访时的94.5%。这种新方法使全科医生的HF GDMT工作量在6个月和2年分别减少36.6%和42.1%,医疗费用在6个月和2年分别减少18.4%和20.3%。血管紧张素受体奈普利素抑制剂/葡萄糖钠共转运蛋白2抑制剂联合治疗的患者心血管死亡率降低20.8%,住院率降低34.8%,2年生活质量改善的堪萨斯城心肌病问卷得分为5.31。对于低风险心衰患者,药剂师主导的优化实现了显著更高的GDMT率,降低了人员医疗保健成本,减少了全科医生的工作量,有助于降低心血管死亡率,减少住院治疗和提高生活质量。在当前工作量压力的背景下,应该考虑在一般实践中广泛实施这种方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.

Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.

Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.

Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.

Optimal guideline-directed medical therapy (GDMT) can reduce mortality, unplanned hospital admissions and improve quality of life for patients suffering from heart failure (HF). However, GDMT remains underused in primary care. Only a minority of patients on HF registers receive optimal GDMT in the UK. This suboptimal care is compounded by a mounting lack of GP capacity and the growing burden of HF.A multisite, quantitative impact analysis was undertaken to evaluate the optimisation of HF patients by a novel pharmacist-led GDMT model in UK primary care.We identified low-risk HF patients suitable for pharmacists' input, including a community validated risk stratification tool-the HF Event STrengthening Score. The primary outcome was to compare the proportion of patients on optimal HF GDMT at 6 months and 2 years with baseline. Secondary outcomes were direct personnel healthcare costs and GP workload. A subgroup analysis was modelled to estimate effect on mortality, hospitalisation and quality of life.A total of 237 patients were included. Pharmacist-led GDMT contributed to the increase of optimal GDMT from 17.7% at baseline to 76.5% at 6 months and 94.5% at 2 years follow-up. The novel approach reduced GPs' HF GDMT workload by 36.6% at 6 months and 42.1% at 2 years and healthcare costs by 18.4% at 6 months and 20.3% at 2 years. Patients with combined angiotensin receptor neprilysin inhibitor/sodium glucose co-transporter 2 inhibitor treatment indicated a reduction of 20.8% in cardiovascular mortality, a reduction of 34.8% in hospitalisations and a 5.31 Kansas City Cardiomyopathy Questionnaire Score for improved quality of life at 2 years.For low-risk HF patients, pharmacist-led optimisation achieved significantly higher GDMT rates, reduced personnel healthcare costs, reduced GPs' workload, contributed to reduced cardiovascular mortality, reduced hospitalisations and improved quality of life. In the context of current workload pressures, this approach should be considered for widespread implementation in general practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Open Quality
BMJ Open Quality Nursing-Leadership and Management
CiteScore
2.20
自引率
0.00%
发文量
226
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信